Sevahealthcare
- PRP Therapy
- Ketamine Therapy
- Arthritis Treatment
- Migraine Treatment
- Stem Cell Therapy
Tulsa, OK
Tulsa supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through Saint Francis Hospital, Hillcrest, and OU-TU School of Community Medicine, and stem cell practice in the area spans midtown, south Tulsa, and the Cherry Street corridor. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. Oklahoma regulates physician practice through the State Board of Medical Licensure and Supervision. There is no Oklahoma-specific stem cell statute, so federal 21 CFR Part 1271 rules apply. The 13 Tulsa clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and Oklahoma Board of Medical Licensure licensure checks.
Regulatory context
Oklahoma cellular therapy is governed by 21 CFR Part 1271. Section 361 covers minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 covers products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, and exosome therapies marketed in Oklahoma for orthopedic, neurologic, and longevity indications are Section 351 biologics that lack FDA approval. Oklahoma's regulatory environment relies on federal law and the Oklahoma Allopathic Medical and Surgical Licensure and Supervision Act.
The FDA has corresponded with Oklahoma providers offering cellular therapies. The Oklahoma State Board of Medical Licensure and Supervision and the Board of Osteopathic Examiners have disciplined physicians for unprofessional conduct including misleading regenerative medicine advertising. The Oklahoma Attorney General can pursue deceptive marketing under the Oklahoma Consumer Protection Act. Oklahoma's smaller market means enforcement is less frequent than in larger states, but federal warning letters apply nationally.